Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates

The facility remains proposed, while additional health-supplement production lines depend on planning, regulatory requirements and available funding.

Rhea-AI Summary

Jyong Biotech (MENS) plans a manufacturing facility and U.S. operations center in Texas to support potential commercialization of its drug candidates. A facility and operations plan has been submitted to local Texas authorities, and the company is preparing formal communications with relevant government agencies.

Jyong expects the proposed facility to have pharmaceutical manufacturing capabilities and is evaluating additional health-supplement production lines, subject to further planning, regulatory requirements and available funding. The company cites competitive land costs, the corporate tax structure, state tax exemptions and manufacturing incentives as reasons for choosing Texas. The U.S. is its highest-priority market. Commercialization of its investigational drugs depends on approval; Jyong currently has no approved drug products for commercial use in any jurisdiction.

3 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Planned Texas manufacturing facility and U.S. operations center would support potential future commercialization, if drug candidates are approved.
• Minor point. Forward-looking: it has not happened yet and may not happen.Proposed facility is expected to include pharmaceutical manufacturing capabilities.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional health-supplement production lines are being evaluated as a possible expansion of the proposed facility.

Negative

• Moderate pointTexas facility remains proposed; formal communications with relevant government agencies are still being prepared.
• Minor point. Forward-looking: it has not happened yet and may not happen.Possible health-supplement production lines depend on further planning, regulatory requirements and available funding.

News Explained

For market context, the company cites a review estimating 12.2 million U.S. men were actively managed for BPH/LUTS in 2015, and identifies about 35% of that population—those in watchful waiting—as its primary target if a candidate is approved.

Key Terms

bph

1 terms

bph medical

"8.7 million American men are potential candidates for treatment of BPH-related LUTS"

Benign prostatic hyperplasia (BPH) is a non‑cancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms such as frequent urination, weak stream, or incomplete bladder emptying. For investors, BPH matters because it creates steady demand for medicines, medical devices and procedures, often producing recurring revenue and sizable market opportunities tied to an aging population; think of it as a plumbing constriction that many older men need treatment to fix.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative is intended to support the Company’s U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, if approved.

Following an evaluation of factors including government policies, market conditions, workforce recruitment and logistics, Jyong Biotech has submitted a facility and operations plan to local government authorities in the State of Texas and is preparing to commence formal communications with the relevant government agencies regarding the relevant procedures.

The Company selected Texas based on factors including competitive land costs, a favorable corporate tax structure, state tax exemptions and manufacturing incentives. The Company currently expects the proposed facility to possess pharmaceutical manufacturing capabilities, and the Company is also evaluating whether the proposed facility may include additional production lines for health supplements, subject, among others, to further planning, regulatory requirements and available funding.

"We believe establishing manufacturing capacity in the United States will support our long-term commercial plans," stated Fu-Feng Kuo, Chairwoman and Chief Executive Officer of Jyong Biotech." Texas offers a favorable business environment and potential state tax incentives, which we believe will allow us to build the infrastructure needed to support the potential commercial activities and operations of our drug candidates, if approved."

The U.S. is Jyong Biotech's highest-priority market due to favorable drug pricing dynamics and the broader international recognition of FDA-approved pharmaceuticals. The Company believes that FDA approvals for its product candidates, if obtained, may facilitate regulatory filings in other markets; however, approval in any other jurisdiction is not assured.

According to a 2012 review published in the Canadian Urological Association Journal, approximately 8.7 million American men are potential candidates for treatment of BPH-related LUTS each year. According to a 2015 review published in The Canadian Journal of Urology, approximately 12.2 million U.S. men were actively managed for BPH/LUTS as of 2015. Based on that review’s breakdown of this actively managed population, the Company believes there is a potential commercial opportunity across the following segments:

• Watchful-Waiting Population: Approximately 35% of actively managed patients are in watchful waiting and receive no pharmacological therapy, and represent the Company's intended primary target population, if new drug candidate is approved.
• Discontinued Treatment Population: An estimated 9.1% of actively managed patients have discontinued drug therapy and returned to watchful waiting, representing a potential secondary target population.
• Current Treatment Population: For the 54.8% of actively managed patients taking chemical medications, the Company believes new drug candidate, if approved, could potentially be evaluated as a combination or alternative therapy.
  

"Our commercial strategy in the U.S. targets a significant patient population," added Chairwoman Kuo." With nearly 35 percent of patients in watchful waiting and almost 10 percent discontinuing drug treatment, we believe our drug candidates, if approved, will address this unmet medical need."

As of the date of this press release, Jyong Biotech does not have any approved drug products available for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Email: vivi.z@jyongbio.com 
Phone: +1 (646) 307-3803

Investor Relations
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 (628) 283-9214

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Jyong Biotech planning to build in Texas?

Jyong Biotech plans a manufacturing facility and U.S. operations center to support potential future commercialization of its investigational drug candidates, if approved. The proposed facility is expected to have pharmaceutical manufacturing capabilities, and the company is evaluating additional health-supplement production lines.

Why is the U.S. Jyong Biotech's highest-priority market?

Jyong Biotech identifies favorable drug pricing dynamics and the broader international recognition of FDA-approved pharmaceuticals as reasons for prioritizing the U.S. It believes FDA approvals, if obtained, may facilitate regulatory filings in other markets, but approval in another jurisdiction is not assured.